Jerini AG Completes Randomization of Last Patient in Phase III Clinical Trial (FAST 1) of Icatibant for the Treatment of Hereditary Angioedema BERLIN, April 24, 2006 (PRIMEZONE) -- Jerini AG (FSE:JI4) reported today the randomization of the last patient in its Phase III clinical trial (FAST 1) of Icatibant for the treatment of hereditary...

Jerini AG Reports Financial Results for Fiscal Year 2005 Highlights of 2005: -- EUR 96.7 million in cash and cash equivalents as of December 31, 2005 -- Successful stock market listing on Prime Standard of the Frankfurt Stock Exchange raised...

Jerini AG Presents Clinical Development Update for Icatibant in the Treatment of Hereditary Angioedema -- On track to report top-line Phase III results in mid-2006 -- Over 350 patients screened in 63 active sites worldwide -- 153 open-label attacks treated in Phase III trials BERLIN, March 6,...

Jerini Reports Increase in Revenues for Third Quarter and for the First Nine Months BERLIN, Dec. 1, 2005 (PRIMEZONE) -- Jerini CEO Schneider-Mergener: "Our partnership with U.S.-based Kos provides the basis for realizing the excellent market potential of Icatibant in North...

Kos and Jerini Sign Exclusive Collaboration and License Agreement for Development, Marketing and Distribution of Icatibant in The United States and Canada -- Kos to develop, market and distribute Icatibant in the U.S. and Canada -- Icatibant, in final Phase III clinical trials for hereditary angioedema (HAE), represents next potential new...